Overview

* Glaukos Q2 2025 net sales rise 30% yr/yr, beating analyst expectations

* The ophthalmic medical technology company raises 2025 net sales guidance to $480 mln-$486 mln

* Q2 adjusted net loss beats analyst estimates

Outlook

* Glaukos ( GKOS ) raises 2025 sales guidance to $480 mln-$486 mln

* Glaukos ( GKOS ) focuses on advancing novel eye disease technologies

Result Drivers

* GROWTH IN GLAUCOMA SALES - Record net sales in glaucoma segment, with U.S. sales up 45% yr/yr

* STRATEGIC EXECUTION - CEO attributes growth to successful execution of strategic plans

* PIPELINE ADVANCEMENT - Continued advancement of novel, dropless platform technologies

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Sales Beat $124.10 $115.50

mln mln (14

Analysts

)

Q2 EPS -$0.34

Q2 Beat -$13.60 -$15.10

Adjusted mln mln (12

Net Analysts

Income )

Q2 Net -$19.70

Income mln

Q2 Gross 78.0%

Margin

Q2 83.0%

Adjusted

Gross

Margin

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Glaukos Corp ( GKOS ) is $120.00, about 21.9% above its July 29 closing price of $93.76

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)